The second trial ruling on the patent dispute between Dong-A ST and AstraZeneca over Forxiga, a diabetes treatment based on SGLT-2 inhibitors, has been postponed. The Patent Court's 5-2 Court postponed the date of the judgment on the trial decision cancellation suit filed by AstraZeneca against Dong-A ST from the 10th to the 17th. The court seems to have been worried in that it was the first case in Korea to try to overcome material patents using a "prodrug" strategy.

Prodrug is evaluated as a different drug, such as an original drug. The original drug and chemical structure differ in some parts of the substituent until immediately before taking it after the drug is produced. However, when a pa